Table 3.
Individual and combined efficacy of commercial antibiotics and biosynthesized AgNPs against pathogenic bacteria.
| Pathogenic Bacteria | Antibiotic | Inhibition Zone |
|
|---|---|---|---|
| Ab | Ab + AgNPs | ||
| P. aeruginosa | Erythromycin | - | 15.0 ± 1.1 |
| Novobiocin | - | 15.0± 0.8 | |
| Vancomycin | - | 13.0± 2.1 | |
| Lincomycin | - | 14.0± 1.5 | |
| Penicillin G | - | 14.0± 1.3 | |
| Oleandomycin | - | 14.0± 1.5 | |
| E. coli | Erythromycin | - | 13.0± 2.2 |
| Novobiocin | - | 11.0± 1.8 | |
| Vancomycin | - | 11.0± 1.8 | |
| Lincomycin | - | 11.0± 1.7 | |
| Penicillin G | - | 12.0± 1.1 | |
| Oleandomycin | - | 11.0 ± 2.0 | |
| S. enterica | Erythromycin | - | 13.0± 1.9 |
| Novobiocin | - | 13.0± 1.6 | |
| Vancomycin | - | 11.0 ± 2.3 | |
| Lincomycin | - | 11.0 ± 1.9 | |
| Penicillin G | - | 10.0 ± 2.1 | |
| Oleandomycin | - | 11.0± 2.5 | |
Notes: Ab: Antibiotic.
Ab + AgNPs: Antibiotics with silver nanoparticles.
Erythromycin (15 μg/disc), Lincomycin (15 μg/disc), Novobiocin (30 μg/disc), Penicillin G (10 μg/disc), Vancomycin (30 μg/disc) and Oleandomycin (15 μg/disc). AgNPs: silver nanoparticles, 30 μL (500 ppm). Each result is a representative of three independent experiment. Results are expressed as means ± standard deviation (SD).